Natural products continue to provide vital treatment options for
cancer. Although their translation into chemotherapeutics is complex, collaborative programs continue to deliver productive pipelines for
cancer chemotherapy. A new
natural product,
seriniquinone, isolated from a marine bacterium of the genus Serinicoccus, demonstrated potent activity over a select set of tumor cell lines with particular selectivity toward
melanoma cell lines. Upon entering the cell, its journey began by localization into the endoplasmic reticulum. Within 3 h, cells treated with
seriniquinone underwent cell death marked by activation of autophagocytosis and gradually terminated through a
caspase-9 apoptotic pathway. Using an immunoaffinity approach followed by multipoint validation, we identified the target of
seriniquinone as the small
protein,
dermcidin. Combined, these findings revealed a small molecule motif in parallel with its therapeutic target, whose potential in
cancer therapy may be significant. This discovery defines a new pharmacophore that displayed selective activity toward a distinct set of cell lines, predominantly
melanoma, within the NCI 60 panel. This selectivity, along with the ease in medicinal chemical modification, provides a key opportunity to design and evaluate new treatments for those
cancers that rely on
dermcidin activity. Further, the use of
dermcidin as a patient preselection
biomarker may accelerate the development of more effective personalized treatments.